ATOM-1
Live / Applied — Second extension granted (statement of use) (as of 05 Sept 2025)
What this means for you
Not registered yet, but its 12 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98355762
- Mark type
- Stylized text
- Filed
- 12 Jan 2024
- Published for opposition
- 17 Sept 2024
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 042 — Scientific and technological services: Providing online non-downloadable computer software platforms for use in developing therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; providing online non-downloadable computer software platforms for use in automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; providing online non-downloadable computer software platforms for use in drug design and development featuring machine-learning algorithms and lab automation tools; research and development of pharmaceuticals, namely, therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; research and development in the fields of biotechnology, DNA, RNA, molecules and proteins; automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; drug design and development featuring machine-learning algorithms and lab automation tools; developing customized software in the field of drug design and development
Owner
- Atomic AI, Inc., South San Francisco, CA, US
- Atomic AI, Inc., South San Francisco, CA, US
Prosecution history
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Sept 2025 — SOU EXTENSION 2 GRANTED
- 04 Sept 2025 — SOU EXTENSION 2 FILED
- 04 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Feb 2025 — SOU EXTENSION 1 GRANTED
- 08 Feb 2025 — SOU EXTENSION 1 FILED
- 07 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Sept 2024 — PUBLISHED FOR OPPOSITION
- 28 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Aug 2024 — ASSIGNED TO EXAMINER
- 06 May 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED